ARS Pharmaceuticals, Inc. SPRY Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s total liabilities & equity?
- ARS Pharmaceuticals, Inc. (SPRY) reported total liabilities & equity of $287.57M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
- ARS Pharmaceuticals, Inc.'s total liabilities & equity decreased by 12.1% year-over-year, from $327.32M to $287.57M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s total liabilities & equity has grown at a -3.7% compound annual growth rate (CAGR), from $394.8M to $327.65M.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.